Lupin Urged To ‘Put US In Order’ As It Slides To Annual Pre-Tax Loss
Analyst: ‘The US Has Not Contributed To EBITDA’
Lupin’s 2021/22 financial year results revealed weakness in its core US generics business amid challenging market conditions. The Indian firm will continue to throw its weight behind its domestic business while rebuilding the US operation with more complex, high-value launches.
